Approval Notice for AREXVY Vaccine: Rare Pediatric Disease Priority Review
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The FDA has approved a product leveraging a rare pediatric disease priority review voucher. This means AREXVY, a vaccine for Respiratory Syncytial Virus, will enter the market faster, helping address urgent health needs in children. Companies with similar products might seek these vouchers to speed up their approval processes.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- AREXVY vaccine gains quick market entry
- Priority review voucher utilized
- Accelerates response to pediatric health needs
Obligations
What this law requires
The FDA must publish notice of the approval of products redeeming rare pediatric disease priority review vouchers.
FDA must publish notice of the issuance of rare pediatric disease priority review vouchers.
Drug developers must apply for and meet specific criteria to qualify for priority review vouchers under the Rare Pediatric Disease Priority Review Voucher Program.
FDA must report the approval of products for which a rare pediatric disease priority review voucher was redeemed.
Sponsors of approved rare pediatric disease product applications must meet certain criteria to be eligible for priority review vouchers.